These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
134 related articles for article (PubMed ID: 17990421)
1. Impact of antibiotic restriction on broad spectrum antibiotic usage in the ICU of a developing country. Siddiqui S; Hussein K; Manasia R; Samad A; Salahuddin N; Zafar A; Hoda MQ J Pak Med Assoc; 2007 Oct; 57(10):484-7. PubMed ID: 17990421 [TBL] [Abstract][Full Text] [Related]
2. The impact of a nationwide antibiotic restriction program on antibiotic usage and resistance against nosocomial pathogens in Turkey. Altunsoy A; Aypak C; Azap A; Ergönül Ö; Balık I Int J Med Sci; 2011; 8(4):339-44. PubMed ID: 21647326 [TBL] [Abstract][Full Text] [Related]
3. Empiric antibiotics pending bronchoalveolar lavage data in patients without pneumonia significantly alters the flora, but not the resistance profile, if a subsequent pneumonia develops. Thakkar RK; Monaghan SF; Adams CA; Stephen A; Connolly MD; Gregg S; Cioffi WG; Heffernan DS J Surg Res; 2013 May; 181(2):323-8. PubMed ID: 22906560 [TBL] [Abstract][Full Text] [Related]
4. Antibiotic prescription in intensive care units in Latin America. Curcio DJ; Rev Argent Microbiol; 2011; 43(3):203-11. PubMed ID: 22430995 [TBL] [Abstract][Full Text] [Related]
5. Prospective drug utilization evaluation of three broad-spectrum antimicrobials: cefepime, piperacillin-tazobactam and meropenem. Raveh D; Muallem-Zilcha E; Greenberg A; Wiener-Well Y; Schlesinger Y; Yinnon AM QJM; 2006 Jun; 99(6):397-406. PubMed ID: 16682440 [TBL] [Abstract][Full Text] [Related]
6. The effect of formulary restriction in the use of antibiotics in an Italian hospital. Bassetti M; Di Biagio A; Rebesco B; Amalfitano ME; Topal J; Bassetti D Eur J Clin Pharmacol; 2001 Sep; 57(6-7):529-34. PubMed ID: 11699621 [TBL] [Abstract][Full Text] [Related]
7. In vitro activity of newer broad spectrum beta-lactam antibiotics against enterobacteriaceae and non-fermenters: a report from Austrian intensive care units. Austrian Carbapenem Susceptibility Surveillance Group. Krause R; Mittermayer H; Feierl G; Allerberger F; Wendelin I; Hirschl A; Reisinger EC Wien Klin Wochenschr; 1999 Jul; 111(14):549-54. PubMed ID: 10467641 [TBL] [Abstract][Full Text] [Related]
8. Implementation and outcomes of hospital-wide computerized antimicrobial approval system and on-the-spot education in a traumatic intensive care unit in Taiwan. Huang TY; Hung CH; Lai LJ; Chuang HJ; Wang CC; Lin PT; Hsu WH J Microbiol Immunol Infect; 2018 Oct; 51(5):672-680. PubMed ID: 29167061 [TBL] [Abstract][Full Text] [Related]
9. Audit and feedback to reduce broad-spectrum antibiotic use among intensive care unit patients: a controlled interrupted time series analysis. Elligsen M; Walker SA; Pinto R; Simor A; Mubareka S; Rachlis A; Allen V; Daneman N Infect Control Hosp Epidemiol; 2012 Apr; 33(4):354-61. PubMed ID: 22418630 [TBL] [Abstract][Full Text] [Related]
10. Impact of de-escalation of beta-lactam antibiotics on the emergence of antibiotic resistance in ICU patients: a retrospective observational study. De Bus L; Denys W; Catteeuw J; Gadeyne B; Vermeulen K; Boelens J; Claeys G; De Waele JJ; Decruyenaere J; Depuydt PO Intensive Care Med; 2016 Jun; 42(6):1029-39. PubMed ID: 27025939 [TBL] [Abstract][Full Text] [Related]
11. Rational use of antibiotics in the intensive care unit: impact on microbial resistance and costs. Geissler A; Gerbeaux P; Granier I; Blanc P; Facon K; Durand-Gasselin J Intensive Care Med; 2003 Jan; 29(1):49-54. PubMed ID: 12528022 [TBL] [Abstract][Full Text] [Related]
12. [Diversity in antibiotic use in intensive care units in Germany]. Meyer E; Schwab F; Schroeren-Boersch B; Rüden H; Gastmeier P Dtsch Med Wochenschr; 2008 Feb; 133(6):235-40. PubMed ID: 18236348 [TBL] [Abstract][Full Text] [Related]
13. Comparison of the effect of ciprofloxacin and Tazocin on the incidence of meticillin-resistant Staphylococcus aureus (MRSA) in an Intensive Care Unit. Aldeyab MA; Hughes CM; Kearney MP; Scott MG; McDowell DA; Hanley J; McMahon MA; Elshibly SM; Bailie R; McElnay JC Int J Antimicrob Agents; 2008 Dec; 32(6):499-504. PubMed ID: 18801646 [TBL] [Abstract][Full Text] [Related]
14. Differences in the changes in resistance patterns to third- and fourth-generation cephalosporins and piperacillin/tazobactam among Klebsiella pneumoniae and Escherichia coli clinical isolates following a restriction policy in a Greek tertiary care hospital. Petrikkos G; Markogiannakis A; Papaparaskevas J; Daikos GL; Stefanakos G; Zissis NP; Avlamis A Int J Antimicrob Agents; 2007 Jan; 29(1):34-8. PubMed ID: 17189092 [TBL] [Abstract][Full Text] [Related]
15. Patient and physician predictors of patient receipt of therapies recommended by a computerized decision support system when initially prescribed broad-spectrum antibiotics: a cohort study. Chow AL; Lye DC; Arah OA J Am Med Inform Assoc; 2016 Apr; 23(e1):e58-70. PubMed ID: 26342216 [TBL] [Abstract][Full Text] [Related]
16. Antibiotic utilization and Pseudomonas aeruginosa resistance in intensive care units. Vojtová V; Kolár M; Hricová K; Uvízl R; Neiser J; Blahut L; Urbánek K New Microbiol; 2011 Jul; 34(3):291-8. PubMed ID: 21811750 [TBL] [Abstract][Full Text] [Related]
17. Reduction of broad-spectrum antibiotic use with computerized decision support in an intensive care unit. Thursky KA; Buising KL; Bak N; Macgregor L; Street AC; Macintyre CR; Presneill JJ; Cade JF; Brown GV Int J Qual Health Care; 2006 Jun; 18(3):224-31. PubMed ID: 16415039 [TBL] [Abstract][Full Text] [Related]
18. Impact of an antibiotic restriction policy on hospital expenditures and bacterial susceptibilities: a lesson from a pediatric institution in a developing country. Sáez-Llorens X; Castrejón de Wong MM; Castaño E; De Suman O; De Morös D; De Atencio I Pediatr Infect Dis J; 2000 Mar; 19(3):200-6. PubMed ID: 10749459 [TBL] [Abstract][Full Text] [Related]
19. In vitro and in vivo activities of piperacillin-tazobactam and meropenem at different inoculum sizes of ESBL-producing Klebsiella pneumoniae. Harada Y; Morinaga Y; Kaku N; Nakamura S; Uno N; Hasegawa H; Izumikawa K; Kohno S; Yanagihara K Clin Microbiol Infect; 2014 Nov; 20(11):O831-9. PubMed ID: 24813594 [TBL] [Abstract][Full Text] [Related]
20. In vitro killing of parenteral beta-lactams against standard and high inocula of extended-spectrum beta-lactamase and non-ESBL producing Klebsiella pneumoniae. Burgess DS; Hall RG Diagn Microbiol Infect Dis; 2004 May; 49(1):41-6. PubMed ID: 15135499 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]